1,6-naphthiridine compounds as SMARCA2 inhibitors useful in the treatment of SMARCA4-deficient cancers

JP2026522124A5Pending Publication Date: 2026-07-13JANSSEN PHARMA NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025576208
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-07-05
Publication Date
2026-07-13

Smart Images

  • Figure 2025008059000001
    Figure 2025008059000001
  • Figure 2025008059000002
    Figure 2025008059000002
  • Figure 2025008059000003
    Figure 2025008059000003
Patent Text Reader

Abstract

The present invention relates to pharmaceutical compounds and pharmaceutical compositions containing said compounds, processes for preparing said compounds, the use of said compounds as inhibitors of the SMARCA2 protein, and the use thereof in the treatment of SMARCA4-deficient cancers, such as SMARCA4-deficient non-small cell lung cancer (NSCLC). [Formula 1] TIFF2026522124000286.tif17128
Need to check novelty before this filing date? Find Prior Art